Biotek-Padciclo

Specialisation

Cornea, Cataract and Refractive Surgery.

Full title

Phase II, multicentre, randomised, double-masked, 4 parallel arms, controlled, 6-month trial designed to evaluate the safety and efficacy of PAD ciclosporin (CsA 0.06% and 0.03%) ophthalmic dispersion administered once daily in combination with lubricant therapy and a 3-month post-treatment safety follow-up in moderate to severe dry eye patients.

Promoter

Biotek.

Start date

May 2016.

Researchers

Principal: Dr José Luis Güell.